Koru Medical transferred with a Buy at B. Riley

B. Riley analyst Kyle Bauser took over coverage of Koru Medical with a Buy rating and $4 price target. Key growth drivers that the firm expects to supplement the core domestic subcutaneous infusion products for self-administration in the home and ambulatory setting offerings include geographic expansion into new markets, such as Japan and Canada, and pre- and post-approval collaborations with biopharma, the analyst tells investors.